US20140171763A1 - Pulse and active pulse spectraphotometry - Google Patents

Abstract

A pulse and active pulse spectraphotometry system comprises a light source adapted to illuminate a tissue site with optical radiation having a plurality of wavelengths selected from at least one of a primary band of about 1620 nm to about 1730 nm and a secondary band of about 1000 nm to about 1380 nm.

Description

REFERENCE TO RELATED APPLICATION
• The present application claims priority benefit under 35 U.S.C. §120 to and is a continuation of U.S. patent application Ser. No. 11/263,404, filed Oct. 31, 2005, entitled “Pulse and Active Pulse Spectraphotometry,” which is a continuation of U.S. patent application Ser. No. 10/371,968, filed Feb. 21, 2003, now U.S. Pat. No. 6,961,598, entitled “Pulse and Active Pulse Spectraphotometry,” which claims priority benefit under 35 U.S.C. §119(e) from U.S. Provisional Application No. 60/358,809, filed Feb. 22, 2002, entitled “Pulse and Active Pulse Spectraphotometry.” The present application incorporates the foregoing disclosures herein by reference.
BACKGROUND OF THE INVENTION
• Various spectral photometric techniques have been developed for the noninvasive monitoring of blood constituent concentrations. In such systems, light of multiple wavelengths is used to illuminate a thin tissue portion of a person, such as a fingertip or earlobe. A spectrum analysis of light transmitted through or reflected from the tissue portion is used to measure the light absorption characteristics of blood flowing through the tissue portion. Utilizing calibration data, the concentration of various blood constituents is then derived from known light absorption characteristics of these blood constituents. In one spectral photometric methodology, the absolute optical spectrum of light received from the tissue portion is measured. In a differential spectral photometric methodology, blood constituent concentrations are derived from photoplethysmograph data that is responsive to blood volume changes. Pulse oximetry systems, which use the latter methodology to monitor hemoglobin constituents, have been particularly successful in becoming the standard of care for patient oxygen saturation monitoring.
SUMMARY OF THE INVENTION
• Spectraphotometry for the noninvasive monitoring of blood constituents, such as blood glucose and total hemoglobin, to name a few, is highly desirable. For example, current methods for accurately measuring blood glucose involve drawing blood from the subject, which can be onerous for diabetics who must take frequent samples to closely monitor blood glucose levels. Spectraphotometry is described under no scattering conditions by the Beer-Lambert law, which states that the concentration c, of an absorbant in solution can be determined by the intensity of light transmitted through the solution, knowing the pathlength d_λ, the intensity of the incident light I_0,λ, and the extinction coefficient ε_i,λ at a particular wavelength λ. The generalized Beer-Lambert law is expressed as
• $\begin{array}{cc}{I}_{\lambda }=I_{0,\lambda }{}^{-d_{\lambda }·{\mu }_{a,\lambda }}& \left(1\right)\\ {\mu }_{a,\lambda }=\sum _{i=1}^n{\varepsilon }_{i,\lambda }·c_i& \left(2\right)\end{array}$
• where μ_a,λ is the bulk absorption coefficient and represents the probability of absorption per unit length. Dividing both sides of EQ. 1 by I_0,λ and taking the logarithm yields
• 
  ln(I_λ/I_0,λ)=−d_λ·μ_a,λ  (3)
• For n wavelengths, EQS. 2 and 3 can be expressed as
• $\begin{array}{cc}\left[\begin{array}{c}\ln \left(I_{{\lambda }_1}/I_{0,{\lambda }_1}\right)\\ ⋮\\ \ln \left(I_{{\lambda }_n}/I_{0,{\lambda }_n}\right)\end{array}\right]=-d\left[\begin{array}{ccc}{\varepsilon }_{1,{\lambda }_1}& \dots & {\varepsilon }_{n,{\lambda }_1}\\ ⋮& \ddots & ⋮\\ {\varepsilon }_{1,{\lambda }_n}& \dots & {\varepsilon }_{n,{\lambda }_n}\end{array}\right]\left[\begin{array}{c}{c}_1\\ ⋮\\ c_n\end{array}\right]& \left(4\right)\end{array}$
• assuming the pathlength is approximately constant at the wavelengths of interest, i.e. d_λ1=d_λ2= . . . d_λn=d. EQ. 4 can be rewritten as
• 
  I(λ)=−dA(λ)C  (5)
• Solving for the constituent concentrations yields
• $\begin{array}{cc}C=-\frac{1}{d}{A\left(\lambda \right)}^{-1}I\left(\lambda \right)& \left(6\right)\end{array}$
• As is well known in the art, a system of linear equations can be solved if there are as many linearly independent equations as unknowns. Applied to EQ. 6, the concentration of a particular blood constituent can be calculated if the number of discrete wavelengths used is equal to the number of significant absorbers that are present and if the absorption characteristics of the significant absorbers are distinguishable at these wavelengths.
• FIG. 1 is ahemoglobin extinction graph100 illustrating the application of the Beer-Lambert law to pulse oximetry. Theextinction graph100 has anextinction coefficient axis101 in units of cm⁻¹/mole and awavelength axis102 in units of nm. AnHb curve110 and an HbO₂curve160 show the light absorption (extinction) properties of reduced hemoglobin and oxyhemoglobin, respectively. In particular, Hb and HbO₂have significantly different absorption characteristics in the red to near IR wavelengths. Indeed,Hb absorption110 is greater than HbO₂absorption160 in the red spectrum and, conversely, HbO₂absorption160 is greater thanHb absorption110 in the near IR spectrum. At red and near IR wavelengths below 970 nm, where water has a significant peak, hemoglobin species are the only significant absorbers. Further, Hb and HbO₂normally are the only hemoglobin species having significant concentrations in blood. Thus, only two wavelengths are needed to resolve the concentrations of Hb and HbO₂. Further, if one red wavelength and one IR wavelength are used, the absorption characteristics of Hb and HbO₂are different enough at these wavelengths to resolve the concentrations of Hb and HbO₂. Typically, a pulse oximetry sensor utilizes a red emitter, such as a light emitting diode (LED) operating at 660 nm, and an IR emitter, such as a LED operating at 905 nm. As a practical matter, pulse oximetry does not explicitly compute a solution to EQ. 6, but computes a ratio of concentrations so that the pathlength, d, may be cancelled, as described with respect to EQ. 7, below.
• FIG. 2 is anabsorption chart200 illustrating the absorption properties of various tissue site components. Theabsorption chart200 has atotal absorption axis201 and atime axis202.Total absorption201 is attributed to time-invariant absorption layers210 and a time-variant absorption layer260. The time-invariant absorption layers210 include atissue absorption layer220, which includes skin, muscle, bone, fat and pigment; a venousblood absorption layer230; and a baseline arterialblood absorption layer240. The time-variant absorption layer260 is due to the pulse-added volume of arterial blood, i.e. the differential volume of arterial blood due to the inflow during systole and the outflow during diastole. The time-variant absorption layer240 has aplethysmograph absorption profile270.
• Pulse oximetry relies on the pulsatile nature of arterial blood to differentiate blood constituent absorption from absorption of other constituents in the surrounding tissues. That is, the sensor signal generated by the pulse-addedarterial blood layer260 is isolated from the signal generated byother layers210, including tissue, venous blood and baseline arterial blood. To do this, pulse spectraphotometry computes a ratio of the AC portion of the detected signal, which is due to the time-variant layer260, with respect to the DC portion of the detected signal, which is due to the time-invariant layers210, for each of multiple wavelengths. Computations of AC/DC ratios provide relative absorption measures that compensate for variations in both incident light intensity and background absorption and, hence, are responsive only to the hemoglobin in the arterial blood. As an example, pulse oximetry typically computes a red (RD) AC/DC ratio and an IR AC/DC ratio. Then, a ratio of ratios is computed, i.e.
• 
  RD/IR=(AC_RD/DC_RD)/(AC_IR/DC_IR)   (7)
• The desired oxygen saturation measurement is then computed empirically from this RD/IR ratio.
• In general, pulse spectraphotometry uses multiple wavelength absorption measures, where the number and value of the wavelengths are based on the number of significant absorbers (analytes) and the absorption characteristics of these analytes. Further, pulse spectraphotometry exploits the plethysmograph absorption profile of arterial blood to cancel the time-invariant absorption contributions from other tissue components and normalization to account for variations in incident light at the different wavelengths. In particular, pulse oximetry systems are generally recognized as providing an accurate measurement of blood oxygen through a comparative measurement of oxyhemoglobin and reduced hemoglobin constituents. The application of pulse spectraphotometry to the accurate measurement of other blood constituents, such as glucose concentration or total hemoglobin, however, poses a number of difficulties, as described below.
• FIG. 3 illustrates is anabsorption graph300 for water in the near infrared (IR) spectrum. Theabsorption graph300 has anabsorption coefficient axis301 in units of cm⁻¹and awavelength axis302 in units of nm. Biological tissues contain a significant percentage of water. Thus, the combination of the light absorption and scattering characteristics of water largely determine the useful range of wavelengths for pulse spectraphotometry. Awater absorption curve310 shows that water absorption increases rapidly with increasingwavelength302 in the near IR, i.e. in the 750 nm to 3000 nm wavelength range. Fortunately for pulse oximetry, water is not a significant absorber compared with hemoglobin in the red and small wavelength portion of the near infrared, i.e. in the 660 to 940 nm wavelength range. Water, however, is a significant absorber in the larger wavelength portion of the near infrared and beyond. In particular, the penetration depth in water of wavelengths around about 1400 nm is 1 mm or less, and the penetration depth decreases rapidly with increasing wavelength beyond 1400 nm.
• Some of the blood constituents of interest are not significant absorbers in the range of wavelengths where photons can penetrate biological tissue. For example, glucose is not a significant absorber in the visible spectrum. Glucose does have strong absorption bands in the far IR, having an absorption peak at 9700 nm, but photon penetration depth at that wavelength is on the order of 10 μm, i.e. around three orders of magnitude less than in the visible and near IR bands used in pulse oximetry.
• When very little analyte is present, such as for blood glucose, the resulting low signal-to-noise ratio (SNR) represents an inherent system limitation for pulse spectraphotometry in the near IR. Further, there are multiple blood constituents, such as hemoglobin, cholesterol and various proteins, such as albumin and gammaglobulins that are significant absorbers in the near IR. Thus, unlike pulse oximetry, more than two wavelengths are required to resolve a particular analyte at these wavelengths.
• One aspect of a pulse spectraphotometry system is a light source adapted to illuminate a tissue site with optical radiation having a plurality of wavelengths selected from at least one of a primary band and a secondary band, where the tissue site has a modulated blood volume. A detector is configured to receive the optical radiation attenuated by the tissue site and to generate a detector output responsive to absorption of the optical radiation within the tissue site. A normalizer operating on the detector output generates a plurality of normalized plethysmographs corresponding to the plurality of wavelengths. Further, a processor is configured to calculate a ratio of fractional volumes of analytes in the blood volume based upon the normalized plethysmographs. In a preferred embodiment, the primary band is in a range of about 1620 nm to about 1730 nm and the secondary band is in a range of about 1000 nm to about 1380 nm. In a more preferred embodiment, the primary band is in a range of about 1620 nm to about 1670 nm. In a most preferred embodiment, at least one of the wavelengths is selected in a range of about 1650 nm±5 nm, in a range of about 1032 nm±5 nm, in a range of about 1097 nm±5 nm or in a range of about 1375 nm±5 nm.
• Another aspect of a pulse spectraphotometry system is a pulse spectraphotometry method comprising the steps of illuminating a tissue site having a pulsatile blood flow with a narrowband optical radiation, time division multiplexing the optical radiation over a plurality of wavelengths and selecting at least a portion of the wavelengths within a range of about 1620 nm to about 1730 nm. Further steps include detecting an attenuated optical radiation from the tissue site as the result of the illuminating step and calculating a ratio of analytes in the blood flow based upon the attenuated optical radiation. In a preferred embodiment, the selecting step comprises the substep of selecting at least one wavelength in a range of about 1620 nm to about 1670 nm. In a more preferred embodiment, the selecting step comprises a substep of selecting at least one wavelength in a range of about 1650 nm±5 nm. In another preferred embodiment, the pulse spectraphotometry method comprises the further step of selecting a second portion of the wavelengths within a range of about 1000 nm to about 1380 nm. In another more preferred embodiment, the selecting a second portion step comprises a substep of selecting at least one wavelength in a range of about 1032 nm±5 nm, in a range of about 1097 nm±5 nm or in a range of about 1375 nm±5 nm.
• Yet another aspect of a pulse spectraphotometry system is an optical radiation means for illuminating a tissue site and a filter means for determining a nominal wavelength of the optical radiation, where the nominal wavelength is selected from a range of about 1620 nm to about 1730 nm. The pulse spectraphotometry system also has a detector means for receiving the optical radiation after transmission through or reflection from the tissue site and for generating a corresponding plethysmograph signal and a processor means for calculating a ratio of analyte portions of pulsatile blood flow within the tissue site based upon the plethysmograph signal. In a preferred embodiment, the nominal wavelength is selected from a range of about 1620 nm to about 1670 nm. In a more preferred embodiment, the nominal wavelength is selected from a range of about 1650 nm±5 nm. In another preferred embodiment, the nominal wavelength is selected from a range of about 1000 nm to about 1380 nm. In another more preferred embodiment, the nominal wavelength is selected from a range of about 1032 nm±5 nm, a range of about 1097 nm±5 nm, or a range of about 1375 nm±5 nm. In yet another preferred embodiment, the nominal wavelength is selected from a range of about 2000 nm to about 2500 nm.
BRIEF DESCRIPTION OF THE DRAWINGS
• FIG. 1 is a graph of oxyhemoglobin and reduced hemoglobin extinction coefficients versus wavelength;
• FIG. 2 is a graph of total tissue and blood light absorption versus time;
• FIG. 3 is a graph of water absorption versus wavelength across a portion of the near infrared spectrum;
• FIG. 4 is a functional block diagram of a pulse spectraphotometry system;
• FIG. 5 is a functional block diagram of a physiological sensor for pulse spectraphotometry; and
• FIG. 6 is a graph of water and glucose absorption versus wavelength including critical wavelength portions of the near infrared spectrum for pulse spectraphotometry.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
• FIG. 4 illustrates a pulse spectraphotometry system having asignal processor400 and asensor500. Herein, the term pulse spectraphotometry is intended to include spectraphotometry based upon the pulsatile characteristics of arterial blood, as described above, and spectraphotometry based upon an active pulse, as described below. Thesensor500 is described in detail with respect toFIG. 5, below. Thesignal processor400 has an analog-to-digital converter (ADC)410, ademodulator420, anactive pulse control430, awavelength control440, atiming control450, a normalizer460, amatrix calculator480 and aratio calculator490. Thesensor500 illuminates a tissue site10 (FIG. 5) with multiple wavelengths, one at a time, and generates asignal output412 that is responsive to the intensity of optical radiation absorbed by the tissue site10 (FIG. 5). Thesignal output412 is a time division multiplexed (TDM) signal with multiple time slots corresponding to the multiple wavelengths. Thetiming control450 determines the time slots. TheADC410 digitizes thesignal output412, and thedemodulator420 separates the individual time slots and corresponding responses. The demodulator output422 is then normalized470, such as by dividing the AC by the DC, as described above, to generate a normalized photoplethysmograph (NPP)472.
• Taking into account scattering in the tissue media and the resulting wavelength dependent optical pathlengths, the transmitted intensity through the media and, hence, thesensor signal output412 can be approximated as
• 
  I_λ≈A_λe^{−mplλ·μa,λ}  (8)
• which is similar in form to EQ. 1, described above, where A_λ is a function of the incident light, the geometry of the tissue media and the tissue media composition; mpl_λ is the wavelength dependent mean pathlength; and μ_a,λ is the bulk absorption coefficient expressed in EQ. 2, above. TheNPP472 can be derived from EQ. 8 as follows
• $\begin{array}{cc}{\mathrm{dI}}_{\lambda }=-{\mathrm{mpl}}_{\lambda }·A_{\lambda }{}^{-{\mathrm{mpl}}_{\lambda }·{\mu }_{a,\lambda }}·{\mu }_{a,\lambda }& \left(9\right)\\ NPP=\frac{{\mathrm{AC}}_{\lambda }}{{\mathrm{DC}}_{\lambda }}=\frac{{\mathrm{dI}}_{\lambda }}{I_{\lambda }}=-{\mathrm{mpl}}_{\lambda }·{\mu }_{a,\lambda }& \left(10\right)\end{array}$
Assume
• 
  dμ_a,λ≈μ_abλ·ΔV/V   (11)
• where μ_abλ is the bulk absorption coefficient of the blood, V is the tissue volume and ΔV is the change in tissue volume due to the pulsatile blood flow. EQ. 10 can then be written as
• $\begin{array}{cc}NPP=-{\mathrm{mpl}}_{\lambda }·{\mu }_{{\mathrm{ab}}_{\lambda }}·v_b& \left(12\right)\\ {\mu }_{{\mathrm{ab}}_{\lambda }}=\sum _iv_i·{\mu }_i;\sum _iv_i=1& \left(13\right)\end{array}$
• which is similar in form to EQS. 2 and 3, described above, where v_b=ΔV/V is the fractional blood volume. Also, v_iis the fractional volume in the blood of the ith analyte and μ_iis the absorption coefficient of the ith analyte. For n wavelengths, EQS. 12 and 13 can be expressed as
• $\begin{array}{cc}\left[\begin{array}{c}NPP_1\\ ⋮\\ NPP_n\end{array}\right]=-\left[\begin{array}{ccc}{\mathrm{mpl}}_{{\lambda }_1}& \dots & 0\\ ⋮& \ddots & ⋮\\ 0& \dots & {\mathrm{mpl}}_{{\lambda }_n}\end{array}\right]\left[\begin{array}{ccc}{\mu }_{1,{\lambda }_1}& \dots & {\mu }_{n,{\lambda }_1}\\ ⋮& \ddots & ⋮\\ {\mu }_{1,{\lambda }_n}& \dots & {\mu }_{n,{\lambda }_n}\end{array}\right]\left[\begin{array}{c}{v}_1\\ ⋮\\ v_n\end{array}\right]v_b& \left(14\right)\end{array}$
• EQ. 14 can be rewritten as
• 
  NPP=−MPL(λ)μ(μ)Vv_b  (15)
• Solving for the analyte fractional volumes yields
• 
  V=−[MPL(λ)μ(λ)]⁻¹NPP/v_b  (16)
• which is similar in form to EQ. 6. Thematrix calculator480 performs the matrix inversion indicated in EQ. 16. Theratio calculator490 is then used to cancel v_band determine a desired ratio of fractional volumes of analytes in the blood. The mean pathlengths can be determined by calibration or separate measurements. A pathlength measurement method is described in U.S. patent application Ser. No. 09/925,982 entitled “Optical Spectroscopy Pathlength Measurement System,” incorporated by reference herein. In particular, using thesensor500 and the wavelengths described in detail with respect toFIG. 6, below, theratio calculator output492 advantageously provides the ratio of the fractional volume of blood glucose to the fractional volume of water in the blood, which is desired for diabetes diagnosis and monitoring.
• Also shown inFIG. 4, anactive pulse control430 provides an active pulse control input to thesensor500. Advantageously, an active pulse mechanism induces a periodic change in the flow of blood through a tissue medium, which can provide a larger AC signal, as described with respect toFIG. 2, above, and a greater SNR as a result. The degree of blood flow modulation is determined by feedback from theNPP472 so as to control the AC signal level. The active pulse mechanism is described in further detail with respect toFIG. 5, below.
• Further shown inFIG. 4, awavelength control440 provides awavelength control input442 to thesensor500. Thewavelength control440 receives input from thetiming control450 and, accordingly, determines the wavelength sequence of optical radiation illuminating the tissue site10 (FIG. 5) in a manner analogous to the LED drive signals transmitted from a pulse oximetry monitor to a pulse oximetry sensor, which is well-known in the art. The sensor wavelength control is described in further detail with respect toFIG. 5, below.
• FIG. 5 illustrates apulse spectraphotometry sensor500 having an ambientlight cover502, alight source510, acondensor lens520, a narrow-band, multiple-wavelength filter530, aminor drive540, a collectinglens550, afiberoptic cable560, adetector570, anamplifier580 and anactive pulse transducer590. Thelight source510 andcondensor lens520 provide broadband optical radiation to thewavelength filter530, which passes selected, narrowband portions of the optical radiation to the collectinglens550. The narrowband optical radiation is coupled to thefiberoptic cable560, which transmits the narrowband optical radiation to illuminate atissue site10 that is shielded from ambient light by thecover502. Thedetector570 generates a current proportional to the intensity of attenuated optical radiation received after transmission through or reflection from the illuminatedtissue site10. The received intensity is responsive to the absorption coefficients of blood constituents, as described with respect to EQS. 8-13, above. Anamplifier580 provides a gain in the detector current and generates asignal output412 to the processor400 (FIG. 4), described above.
• As shown inFIG. 5, thewavelength filter530 has aninput minor532, anoutput mirror534, aparabolic mirror536 and anoptical filter array538. Theinput mirror532 and output minor534 are rotatable according to drivesignals542 from themirror drive540. As such, the mirror drive540 controls the optical path of light around theparabolic mirror536 and through a particular optical filter in theoptical filter array538. Each optical filter in theoptical filter array538 is manufactured to a different narrow passband. Thus, thewavelength filter530 determines the nominal wavelength of optical radiation that illuminates thetissue site10 at any particular time. Thewavelength control input442 from the signal processor400 (FIG. 4) synchronizes the timing of theinput minor532 andoutput mirror534 rotations and, accordingly, the tissue illumination wavelength and the characteristics of theTDM signal output412, described with respect toFIG. 4, above.
• Also shown inFIG. 5 is theactive pulse transducer590, which modulates the blood flow at thetissue site10 according to the activepulse control input432, described with respect toFIG. 4, above. In one embodiment, the active pulse transducer is a pressure device applied to a patient's digit. The pressure device may be, for example, a cuff having a bladder that periodically fills and empties with a gas or liquid, such as air or water. Although shown separate from the sensor inFIG. 5, thetransducer590 may be an integral part of the sensor. Active pulse apparatuses and methods are described in U.S. Pat. No. 6,151,516 entitled “Active Pulse Blood Constituent Monitoring,” incorporated by reference herein.
• In one sensor embodiment, thelight source510 is a high intensity incandescent lamp such that several mw of power is introduced into a tissue site, e.g. a finger, at each wavelength. Thefilter array538 utilizes multiple Fabry-Perot optical interference filters each having a 10 nm bandwidth. The detector is a InGaAs photodiode having a 2 mm -3 mm diameter, a useful response bandwidth in the range of 850 nm to 1700 nm and the highest possible intrinsic shunt resistance. The amplifier is a transimpedance amplifier such as Analog Devices743, having a feedback resistance in the range of 20 to 40 MΩ. The TDM signal output412 (FIG. 4) switches wavelengths at a 40 Hz rate.
• FIG. 6 is agraph600 having alogarithmic absorption axis601 in units of cm⁻¹versus alinear wavelength axis602 in units of nm. Plotted on thegraph600 is awater absorption curve610 andglucose absorption curve660. In a preferred embodiment, the pulse spectraphotometry system is adapted to operate in aprimary wavelength band630 having a range of about 1620 nm to about 1730 nm. In a more preferred embodiment, the pulse spectraphotometry system is adapted to operate in a sub-band of theprimary band630 having a range of about 1620 nm to about 1670 nm. In a most preferred embodiment, the pulse spectraphotometry system is adapted to operate at a nominal wavelength of about 1650 nm±5 nm.
• In a preferred embodiment, the pulse spectraphotometry system may also be adapted to operate in asecondary wavelength band650 having a range of about 1000 nm to about 1380 nm. In a more preferred embodiment, the pulse spectraphotometry system may also adapted to operate at a nominal wavelength around about 1032 nm±5 nm and/or 1097 nm±5 nm, where water and glucose are isobestic. The pulse spectraphotometry system may also be adapted to operate at a nominal wavelength around about 1375 nm±5 nm where water has about the same absorption as in the primary wavelength band. Although the wavelength bands of about 1620 nm to about 1730 nm and of about 1000 nm to about 1380 nm are denoted above as primary and secondary wavelength bands, respectively, the pulse spectraphotometry system may operate solely within the primary wavelength band, solely within the secondary wavelength band or concurrently within both bands.
• As shown inFIG. 6, the preferred embodiment encompasses a critical range of wavelengths for a pulse spectraphotometry system, as described herein. Water absorption rapidly increases an order of magnitude between 1300 nm and 1400 nm and two orders of magnitude between 1300 nm and 1900 nm. Water accounts for a significant percentage of blood, interstitial fluids and other tissue. Further, the intensity of optical radiation transmitted through tissue decreases exponentially with absorption, as described with respect to EQ. 1, above. Accordingly, for the same input intensity, the detected output intensity, i.e. the DC output of the detector570 (FIG. 5), is roughly 200 times less at 1400 nm as compared to 1300 nm. The result is that the signal drops below the electronic noise present in the photodiode and preamp at wavelengths much above 1300 nm. There is a small range of wavelengths in theprimary band630, which encompasses the preferred range of wavelengths, where it is very difficult, but advantageous, to operate the pulse spectraphotometry system. Within this range, water absorption drops to a value roughly equal to its value around 1380 nm, and it is possible to obtain a working plethysmograph, but only by minimizing all noise sources, including the elimination of ambient light; the selection of low noise electronic components, such as described with respect toFIG. 5, above; and careful component layout and interconnection to avoid noise sources such as crosstalk and ground noise, as is well-known in the art.
• There are several advantages of theprimary band630 of wavelengths for the spectraphotometric determination of certain blood constituents. At least five blood constituents of significance are in the near IR, including water, glucose, hemoglobin, urea and protein. In one embodiment, the pulse spectraphotometry system operates over at least five wavelengths for resolution of these analytes. The absorption characteristics of these analytes must be sufficiently different at the operating wavelengths to insure a robust solution, as determined by the condition number of the resulting matrix, as is well known in the art. Operating within theprimary band630 and thesecondary band650 increases the variation in absorption characteristics. In particular, there is a crossover of water absorption and glucose absorption between 1380 nm and 1620 nm, which allows glucose to be more easily distinguished from water.
• Another significant advantage of theprimary band630 is that glucose absorption is an order of magnitude larger within that band than for thesecondary band650, i.e. at wavelengths below 1380 nm. Because intensity varies exponentially with absorption, as described with respect to EQ. 1, measurements derived from theprimary band630 are significantly more sensitive to variations in blood glucose than those derived from thesecondary band650.
• Yet another advantage to theprimary band630 is that, due to the higher absorption of at least some blood constituents in the primary band, including water and glucose, the plethysmograph signal is larger in magnitude in theprimary band630 than for thesecondary band650. Although the SNR of the plethysmograph signal is lower in theprimary band630, the larger absolute magnitude provides a greater dynamic range for blood constituent measurements.
• Although aprimary band630 andsecondary band650 are described above with respect to a sensor500 (FIG. 5) configured to transmit light through a tissue site10 (FIG. 5), in another embodiment, the sensor500 (FIG. 5) may be configured to detect illumination reflected from a tissue site10 (FIG. 5). Because such a reflectance sensor suffers less tissue absorption than a transmission sensor, theprimary band630 may be somewhat broader, in the range of about 1575 nm to 1775 nm and a tertiary band of wavelengths in the range of about 2000 nm to about 2500 nm may be utilized.
• A pulse and active pulse spectraphotometry system has been disclosed in detail in connection with various embodiments. These embodiments are disclosed by way of examples only and are not to limit the scope of the claims that follow. One of ordinary skill in the art will appreciate many variations and modifications within the scope of this invention.

Claims (21)

1-20. (canceled)

21. A pulse spectraphotometry system comprising:

a light source configured to illuminate a tissue site with optical radiation at a first group of discrete wavelengths and a second group of discrete wavelengths, the first group of discrete wavelengths comprising at least some wavelengths different from the second group of discrete wavelengths, the tissue site having a modulated blood volume;

a detector configured to detect the optical radiation attenuated by the tissue site and generate an output signal responsive to absorption of the optical radiation by the tissue site; and

a processor configured to determine one or more measurement values of an analyte in the modulated blood volume based on the output signal,

wherein the first group of discrete wavelengths comprises one or more wavelengths from a group of about 1050 nm, about 1200 nm, about 1270 nm, about 1300 nm, and about 1330 nm.

22. The pulse spectraphotometry system ofclaim 21, wherein the first group of discrete wavelengths comprises two or more wavelengths from the group of about 1050 nm, about 1200 nm, about 1270 nm, about 1300 nm, and about 1330 nm.

23. The pulse spectraphotometry system ofclaim 22, wherein the first group of discrete wavelengths comprises three or more wavelengths from the group of about 1050 nm, about 1200 nm, about 1270 nm, about 1300 nm, and about 1330 nm.

24. The pulse spectraphotometry system ofclaim 22, wherein the second group of discrete wavelengths comprises one or more wavelengths from a group of about 1615 nm, about 1630 nm, and about 1660 nm.

25. The pulse spectraphotometry system ofclaim 24, wherein the second group of discrete wavelengths comprises two or more wavelengths from the group of about 1615 nm, about 1630 nm, and about 1660 nm.

26. The pulse spectraphotometry system ofclaim 21, wherein the second group of discrete wavelengths comprises one or more wavelengths from a group of about 1615 nm, about 1630 nm, and about 1660 nm.

27. The pulse spectraphotometry system ofclaim 26, wherein the second group of discrete wavelengths comprises two or more wavelengths from the group of about 1615 nm, about 1630 nm, and about 1660 nm.

28. The pulse spectraphotometry system ofclaim 27, wherein the second group of discrete wavelengths comprises all wavelengths from the group of about 1615 nm, about 1630 nm, and about 1660 nm.

29. The pulse spectraphotometry system ofclaim 21, wherein the analyte comprises glucose.

30. The pulse spectraphotometry system ofclaim 21, wherein the analyte comprises hemoglobin.

31. A pulse spectraphotometry method comprising:

selecting a discrete wavelength from a first group of discrete wavelengths and a second group of discrete wavelengths, the first group of discrete wavelengths comprising at least some wavelengths different from the second group of discrete wavelengths;

illuminating a tissue site with optical radiation at the selected discrete wavelength, the tissue site having a modulated blood volume;

detecting the optical radiation attenuated by the tissue site;

generating an output signal responsive to absorption of the optical radiation by the tissue site; and

determining one or more measurement values of an analyte in the modulated blood volume based on the output signal,

wherein the first group of discrete wavelengths comprises one or more wavelengths from a group of about 1050 nm, about 1200 nm, about 1270 nm, about 1300 nm, and about 1330 nm, and

wherein the selected discrete wavelength comprises one discrete wavelength of the first group of discrete wavelengths.

32. The pulse spectraphotometry method ofclaim 31, wherein the first group of discrete wavelengths comprises two or more wavelengths from the group of about 1050 nm, about 1200 nm, about 1270 nm, about 1300 nm, and about 1330 nm.

33. The pulse spectraphotometry method ofclaim 32, wherein the first group of discrete wavelengths comprises three or more wavelengths from the group of about 1050 nm, about 1200 nm, about 1270 nm, about 1300 nm, and about 1330 nm.

34. The pulse spectraphotometry method ofclaim 32, wherein the second group of discrete wavelengths comprises one or more wavelengths from a group of about 1615 nm, about 1630 nm, and about 1660 nm.

35. The pulse spectraphotometry method ofclaim 34, wherein the second group of discrete wavelengths comprises two or more wavelengths from the group of about 1615 nm, about 1630 nm, and about 1660 nm.

36. The pulse spectraphotometry method ofclaim 31, wherein the second group of discrete wavelengths comprises one or more wavelengths from a group of about 1615 nm, about 1630 nm, and about 1660 nm.

37. The pulse spectraphotometry method ofclaim 36, wherein the second group of discrete wavelengths comprises two or more wavelengths from the group of about 1615 nm, about 1630 nm, and about 1660 nm.

38. The pulse spectraphotometry method ofclaim 31, wherein the analyte comprises glucose.

39. The pulse spectraphotometry method ofclaim 31, wherein the analyte comprises hemoglobin.

40. A pulse spectraphotometry system comprising:

a light source configured to illuminate a tissue site with optical radiation at a first group of discrete wavelengths and a second group of discrete wavelengths, the first group of discrete wavelengths comprising at least some wavelengths different from the second group of discrete wavelengths, the tissue site having a modulated blood volume;

a detector configured to detect the optical radiation attenuated by the tissue site and generate an output signal responsive to absorption of the optical radiation by the tissue site; and

means for calculating one or more measurement values of an analyte in the modulated blood volume based on the output signal,

wherein the first group of discrete wavelengths comprises one or more wavelengths from a group of about 1050 nm, about 1200 nm, about 1270 nm, about 1300 nm, and about 1330 nm.

Images